[ad_1] Pfizer‘s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer’s clinical trial on more than 34,000 older adults over two RSV seasons. The latest data is specifically on…
[ad_1] Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images GlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory syncytial virus, or RSV, remained effective across two seasons of the disease. A single dose of the shot was 67.2% effective in preventing lower respiratory tract…
[ad_1] A pharmacist prepares to administer Covid-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center in Chicago, Illinois, Sept. 9, 2022. Scott Olson | Getty Images The U.S. Food and Drug Administration‘s Covid strain selection for the next round of shots puts Pfizer, Moderna…
[ad_1] A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S. Food and Drug Administration‘s independent panel of advisors on Thursday recommended that updated Covid shots for the fall and winter target one of the XBB…
[ad_1] Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty Images Novavax has a clear message for Wall Street: The cash-strapped Covid vaccine maker sees a pathway to survival. Maryland-based Novavax said as much last…
[ad_1] A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. Scott Olson | Getty Images Three years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their work is…
[ad_1] Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images The Food and Drug Administration’s independent panel of advisors on Thursday recommended full approval of Pfizer’s vaccine that protects infants from RSV, but raised safety concerns over premature births that may be tied to the shot. The committee unanimously said…
[ad_1] Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images U.S. Food and Drug Administration staff on Tuesday said Pfizer’s vaccine that protects infants from respiratory syncytial virus has “generally favorable” safety data. The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday, when a…
[ad_1] A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages 60 and older. The approval, the first ever globally by a regulatory body for an RSV vaccine, is a decisive victory for GSK in a…
